Home
Storia in 3 fonti
India warns of misuse risk from cheap weight-loss jabs
India’s health ministry warned Tuesday of the risks of unregulated use of weight-loss drugs, as low-cost generic versions hit the market, stepping up inspections and enforcement across the pharmaceutical supply chain. The warning comes after patents on semaglutide — the active ingredient in drugs such as Ozempic and Wegovy — expired on March 20 in India, the world’s largest supplier of generic medicines. Generic versions of the GLP-1 drugs — referring to the hormone that regulates blood glucose levels and appetite — will slash costs and transform the global fight against obesity.
- ·
thehindu.com
Generic semaglutide widens access, but doctors warn of misuse and quality risks
Generic semaglutide increases accessibility, but doctors caution against misuse and quality concerns
- ·
cnbc.com
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top
Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.
- ·
arabnews.com
India warns of misuse risk from cheap weight-loss jabs
India’s health ministry warned Tuesday of the risks of unregulated use of weight-loss drugs, as low-cost generic versions hit the market, stepping up inspections and enforcement…
- ·
Centre intensifies regulatory surveillance over weight loss drugs
India intensifies regulatory measures on weight loss drugs to prevent unauthorized sales and ensure safe medical use.
- ·
India warns of misuse of low-cost weight-loss drugs as Ozempic generics enter market
NEW DELHI: India’s Health Ministry warned on Tuesday of the unregulated use of weight-loss drugs, as cheap generic versions of blockbuster diabetes medications such as Ozempic…